Myovant’s Myfembree Label Expansion Plan Stumbles in FDA Review

Myovant Sciences, a subsidiary of Sumitomo Pharma, has received a letter from the US FDA that appears to cast a cloud over its bid to expand the label of Myfembree (relugolix + estradiol + norethindrone acetate) into an additional endometriosis...read more